Remove 2016 Remove Pharma Remove Physicians Remove Prescription
article thumbnail

Veradigm® Digital Health Media Works to Message the Right Physicians at the Right Time

PM360

As pharma reps’ access to physicians continues to decline, this case study examines the effectiveness of reaching physicians through other means—the EHR. Today’s physicians struggle to balance the increasing demands of patient loads, electronic health record (EHR) systems, and time spent on administrative tasks.

article thumbnail

Health consumers: A long way off

World of DTC Marketing

Our healthcare system makes too much money for insurers, PBM’s and pharma companies to change. In 2016, consumers told Aflac that enrolling in health insurance should feel like an experience on Amazon. It’s simple: people trust each other more than pharma companies who they view with a high degree of skepticism.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

4 Ways to Meet the Needs of an Increasing Health-conscious Audience

PM360

Healthcare and pharma companies are watching this trend and refining their strategies to meet tomorrow’s health consumer. Prescription refills can now be placed with a simple click on a patient portal. Pharma marketing teams must be bold to keep building trust and long-term loyalty.

Retail 97
article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth. Non-COVID prescription medicines didn’t stop launching during the pandemic — approvals by both the FDA and the EMA were, in fact historically high in both 2020 and 2021. The scope of the problem.

Doctors 57
article thumbnail

Humira biosimilars set the stage for long-awaited 2023 US launches

Pharmaceutical Technology

Others are made by big pharma giants like Boehringer Ingelheim , Novartis , or Pfizer , which has raised the expectations for a competitive market. . Indeed, Amgen’s biosimilar was approved in September 2016, but the company was not able to launch it until January 2023 in the US. Biosimilar uptake could be more gradual.

Marketing 104